Current Oncology

OCT 21, 2026 · JOURNAL ARTICLE

Association Between the Number of Invasive Tumor Foci and Axillary Nodal Burden in Multifocal and Multicentric Breast Cancer

Current Oncology

Multifocal and multicentric (MF/MC) breast cancers are associated with increased axillary lymph node involvement, but the relevance of the number of invasive tumor foci is less cle

OCT 20, 2026 · JOURNAL ARTICLE

Integrated Radiobiotherapy: A State-Based Framework for Response-Adaptive Combination Oncology

Current Oncology

Background: Cancer care increasingly requires coordinated use of systemic therapy, targeted radionuclide therapy (TRT), and external-beam radiotherapy (EBRT), yet clinical workflow

OCT 20, 2026 · JOURNAL ARTICLE

Cancer-Specific Survival in Octogenarian Breast Cancer Patients: A Competing Risk Analysis of Prognostic Factors

Current Oncology

Background: This study evaluated long-term survival outcomes in breast cancer patients aged ≥80 years, focusing on how prognostic factors change when competing mortality risks are

OCT 19, 2026 · JOURNAL ARTICLE

Electroacupuncture Combined with Cognitive Behavioral Therapy for Insomnia Alleviates Insomnia–Anxiety Comorbidity in Gynecological Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial

Current Oncology

Insomnia and anxiety affect many gynecological cancer patients on chemotherapy, and non-pharmacological options are limited. This randomized trial examined whether adding electroac

OCT 16, 2026 · JOURNAL ARTICLE

[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing

Current Oncology

Introducing [177Lu]Lu-PSMA-617 into metastatic hormone-sensitive prostate cancer (mHSPC) raises questions about patient selection and treatment sequencing. This non-systematic narr

OCT 15, 2026 · JOURNAL ARTICLE

A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody–Drug Conjugates, and Targeted Therapies

Current Oncology

Platinum-resistant ovarian cancer (PROC) has historically been treated with sequential non-platinum chemotherapy, with bevacizumab added when appropriate. The therapeutic landscape

OCT 14, 2026 · JOURNAL ARTICLE

Translational Challenges and Strategies for Antibody Therapeutics in Glioblastoma

Current Oncology

Glioblastoma (GBM) remains difficult to control. Monoclonal antibodies (mAbs) have transformed the treatment of several extracranial cancers, but they have not consistently improve

OCT 12, 2026 · JOURNAL ARTICLE

Triple Genetic Alterations (EGFR Mutation, ALK Fusion, and MET Polysomy) in Gynecological Metastasis of Lung Adenocarcinoma Patient with Acquired Resistance to Furmonertinib: A Case Report

Current Oncology

For advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, targeted therapy is the standard first-line treatment, but acquired resistan